Andrew Buesking

Andrew Buesking has extensive work experience in the pharmaceutical and biotechnology industry. Andrew is currently employed at Prelude Therapeutics as the Director of Chemistry, a role they have held since August 2022. Prior to this, they worked at Prelude Therapeutics as the Associate Director of Chemistry from August 2020 to July 2022. Before joining Prelude Therapeutics, Andrew worked at Incyte, where they held various positions including Principal Investigator from August 2018 to August 2020, Senior Research Investigator from February 2016 to August 2018, and Research Investigator from April 2014 to February 2016. Andrew'scareer began at Eli Lilly and Company as a High Throughput Medicinal Chemistry Intern in May 2008.

Andrew Buesking earned a Bachelor of Science (BS) degree in Biochemistry from Purdue University from 2005 to 2009. Andrew then attended the University of California, Berkeley from 2009 to 2010, focusing on Chemistry. Andrew furthered their education at Yale University from 2010 to 2014, and received a Doctor of Philosophy (PhD) degree in Chemistry.